Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Feb;86(2):154-225.
doi: 10.1016/j.jinf.2022.11.011. Epub 2022 Nov 18.

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Robert Marcec  1 , Vinko Michael Dodig  1 , Robert Likic  2
Affiliations
Meta-Analysis

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Robert Marcec et al. J Infect. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest No conflicts of interest to declare.

Figures

Fig 1
Fig. 1
Forest plot recreating the original meta-analysis by Cheema, H. A. et al. regarding the effect of fluvoxamine on COVID-19 outpatient hospitalisation risk outcome (Fig. 1A). Reanalysis of the hospitalisation outcome with inclusion of data from the TOGETHER trial (Reis, 2021) on Fig. 1B and with the additional inclusion of data from the recently published preprint of the ACTIV-6 study on Fig. 1C.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Cheema H.A., et al. Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Infect. 2022;1:1–11. - PMC - PubMed
    1. Lee T.C., et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open. 2022;5 - PMC - PubMed
    1. Reis G., et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed
    1. McCarthy, M.W. et al. Fluvoxamine for outpatient treatment of COVID-19: a decentralized, placebo-controlled, randomized, platform clinical trial. medRxiv 2022.10.17.22281178 (2022). doi: 10.1101/2022.10.17.22281178. - DOI